MAKOWER JOSHUA 4
4 · Monte Rosa Therapeutics, Inc. · Filed Jun 30, 2021
Insider Transaction Report
Form 4
MAKOWER JOSHUA
10% Owner
Transactions
- Conversion
Common Stock
2021-06-28+2,715,968→ 2,715,968 total(indirect: See Note 2) - Purchase
Common Stock
2021-06-28$19.00/sh+1,050,000$19,950,000→ 7,692,298 total(indirect: See Note 2) - Conversion
Series B convertible preferred stock
2021-06-28−11,500,000→ 0 total(indirect: See Note 2)→ Common Stock (3,257,328 underlying) - Conversion
Series C convertible preferred Stock
2021-06-28−2,361,912→ 0 total(indirect: See Note 2)→ Common Stock (669,002 underlying) - Conversion
Common Stock
2021-06-28+3,257,328→ 5,973,296 total(indirect: See Note 2) - Conversion
Common Stock
2021-06-28+669,002→ 6,642,298 total(indirect: See Note 2) - Conversion
Series A-2 convertible preferred stock
2021-06-28−9,588,725→ 0 total(indirect: See Note 2)→ Common Stock (2,715,968 underlying)
Footnotes (2)
- [F1]Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.
- [F2]The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.